Safety and activity of the immune modulator HE2000 on the incidence of tuberculosis and other opportunistic infections in AIDS patients.
Twenty-five AIDS patients were treated with HE2000, a synthetic adrenal hormone. The drug was well tolerated and safe and reduced both the incidence of tuberculosis coinfection by 42.2% (P < 0.05) and the cumulative incidence of opportunistic infections (P < 0.05). These results warrant further clinical investigation of HE2000.
Stickney
Dwight R
DR
Hollis-Eden Pharmaceuticals, Inc., 4435 Eastgate Mall, Suite 400, San Diego, CA 92121, USA. dstickney@holliseden.com
Noveljic
Zoja
Z
Garsd
Armando
A
Destiche
Daniel A
DA
Frincke
James M
JM
D017088:AIDS-Related Opportunistic Infections / Q000453:epidemiology* / Q000517:prevention & control; D000163:Acquired Immunodeficiency Syndrome / Q000150:complications* / Q000188:drug therapy / Q000453:epidemiology; D000328:Adult; D000681:Amylases / Q000097:blood; D000738:Androsterone / Q000009:adverse effects / Q000031:analogs & derivatives / Q000494:pharmacology; D018791:CD4 Lymphocyte Count; D003967:Diarrhea / Q000139:chemically induced; D004311:Double-Blind Method; D004361:Drug Tolerance / Q000276:immunology; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects / Q000627:therapeutic use*; D015994:Incidence; D008297:Male; D008875:Middle Aged; D014376:Tuberculosis / Q000150:complications* / Q000453:epidemiology*; D019562:Viral Load
C523751:16alpha-bromo-3beta-hydroxy-5alpha-androstan-17-one; D007155:Immunologic Factors; D000738:Androsterone; D000681:Amylases